Management of Relapsed/Refractory Epithelial Ovarian Cancer: Current Standards and Novel Approaches
Approximately 60% to 70% of epithelial ovarian cancers are diagnosed at an advanced stage. Treatment of advanced disease involves cytoreductive surgery followed by systemic treatment with paclitaxel and platinum. Overall response rates are high, ranging from 70–80%; however, 70–80% of responders wil...
Main Authors: | Hao Lin, Chan-Chao Changchien |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2007-12-01
|
Series: | Taiwanese Journal of Obstetrics & Gynecology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1028455908600078 |
Similar Items
-
Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient
by: Nicoletta Colombo
Published: (2014-12-01) -
New Achievements from Molecular Biology and Treatment Options for Refractory/Relapsed Ovarian Cancer—A Systematic Review
by: Cornelia Bachmann
Published: (2023-11-01) -
A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia
by: Lilit Harutyunyan, et al.
Published: (2024-03-01) -
Practical aspects of treating relapsed BRCA-associated ovarian cancer
by: A. A. Rumyantse, et al.
Published: (2019-12-01) -
The impact of thrombocytosis on the long term outcomes in relapsed ovarian cancer
by: Irina Balescu, et al.
Published: (2023-03-01)